Compounded Tirzepatide alternatives — when to consider switching
If Compounded Tirzepatideisn't working as expected, isn't covered by your insurance, side effects are intolerable, or you want to try something with different efficacy profile, several FDA-approved alternatives exist within the GLP-1 family. This page compares each on efficacy, dosing schedule, cost, and switching considerations.
The GLP-1 family — your alternatives
Single GLP-1 receptor agonists
- Semaglutide (Ozempic for diabetes, Wegovy for weight loss, Rybelsus oral) — Novo Nordisk
- Liraglutide (Victoza for diabetes, Saxenda for weight loss) — Novo Nordisk
- Dulaglutide (Trulicity for diabetes) — Eli Lilly
- Exenatide (Byetta, Bydureon for diabetes) — AstraZeneca
Dual GIP/GLP-1 receptor co-agonists
- Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) — Eli Lilly
Efficacy comparison — at-a-glance
Mean body-weight reduction in pivotal trials (higher = more weight loss):
- Tirzepatide (Mounjaro / Zepbound): ~22.5% at 72 weeks (SURMOUNT-1)
- Semaglutide 2.4mg (Wegovy): ~14.9% at 68 weeks (STEP-1)
- Semaglutide 1.0mg (Ozempic): ~6-8% at 68 weeks (varies by trial)
- Liraglutide 3.0mg (Saxenda): ~8% at 56 weeks (SCALE)
- Dulaglutide (Trulicity): ~3-5% (not a weight-loss-specific indication)
Dosing frequency comparison
- Once weekly: Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Bydureon
- Once daily: Saxenda, Victoza
- Twice daily: Byetta (older formulation)
- Oral (daily): Rybelsus
Switching considerations
Switching within the same active ingredient
Switching between Mounjaro ↔ Zepbound (both tirzepatide), or Ozempic ↔ Wegovy (both semaglutide), or Victoza ↔ Saxenda (both liraglutide), is straightforward because the active ingredient is identical. The main differences are dose (Wegovy goes to 2.4mg vs Ozempic max ~2mg) and labeled indication (weight loss vs diabetes). Prescribers can transition without dose reset.
Switching between different active ingredients
Switching from semaglutide → tirzepatide (or vice versa), or to/from liraglutide, typically requires restarting titrationfrom the new drug's lowest dose. This is because:
- Different doses correspond to different molecular potencies
- Tolerability differs — even if you tolerated full-dose semaglutide, you may need to titrate up on tirzepatide
- Insurance coverage often requires fresh prior authorization for the new drug
Switching to compounded versions
Some patients switch from FDA-brand Compounded Tirzepatide to a compounded version of the same active ingredient for cost reasons. Important caveats:
- Compounded versions are not FDA-approved formulations
- Dose conversions may not be 1:1 — verify with the compounding pharmacy
- Quality varies by compounding pharmacy (use state-licensed 503A or FDA-registered 503B)
- Following 2025 FDA shortage resolution, the legal basis for compounding GLP-1s has narrowed
See our medical disclaimer for full compounded GLP-1 risk discussion.
Cost comparison
Cash-pay prices vary widely. Approximate ranges per month:
- Compounded semaglutide / tirzepatide via partner: $199–$399
- FDA-brand via telehealth partner subscription: $349–$899
- FDA-brand via manufacturer direct (LillyDirect / NovoCare): varies — often discounted
- Retail without insurance: $900–$1,300+
FAQ about Compounded Tirzepatide alternatives
How do I know if I should switch?
Common reasons to consider switching: insufficient weight loss at maximum tolerated dose, intolerable side effects despite slow titration, cost / insurance changes, or your prescriber recommends a switch based on your individual response. Always discuss with your prescriber rather than self-switching.
Can I take two GLP-1s at the same time?
No. Combining two GLP-1 receptor agonists provides no additional benefit and dramatically increases side-effect risk. Standard practice is to switch from one to another, not combine.
What if all GLP-1s don't work for me?
GLP-1s help most but not all patients. Alternatives outside the GLP-1 class include older medications (phentermine, naltrexone-bupropion combination, topiramate, orlistat), and for severe obesity, bariatric surgery. Discuss with your prescriber.
Compare specific pairs head-to-head on our comparison hub. Full medical disclaimer.